Albala DM - Search Results

1

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.

Shore ND, Antonarakis ES, Cookson MS, Crawford ED, Morgans AK, Albala DM, Hafron J, Harris RG, Saltzstein D, Brown GA, Henderson J, Lowentritt B, Spier JM, Concepcion R. Shore ND, et al. Among authors: albala dm. Prostate. 2020 May;80(6):527-544. doi: 10.1002/pros.23967. Epub 2020 Mar 4. Prostate. 2020. PMID: 32130741 Free PMC article. Review.

2

Advanced prostate cancer in large group practices.

Albala DM, Kirsh GM, Shore ND. Albala DM, et al. Rev Urol. 2016;18(4):226-230. doi: 10.3909/riu0737. Rev Urol. 2016. PMID: 28127265 Free PMC article. No abstract available.

3

The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.

Mouraviev V, Mariados N, Albala D, Concepcion RS, Shore ND, Sims RB, Emberton M, Pieczonka CM. Mouraviev V, et al. Rev Urol. 2014;16(3):122-30. Rev Urol. 2014. PMID: 25337042 Free PMC article. Review.

4

Prostate Cancer Academy 2016: Presentation summaries.

Crawford ED, Albala DM, Wysocki JS, Lepor H, Ross AE, Finkelstein SE, Keane T, Freedland S, Harris R, Shore ND, Ryan CJ. Crawford ED, et al. Among authors: albala dm. Rev Urol. 2016;18(4):205-213. doi: 10.3909/riuPCA2016. Rev Urol. 2016. PMID: 28127262 Free PMC article. No abstract available.

5

Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.

Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J. Badani KK, et al. BJU Int. 2015 Mar;115(3):419-29. doi: 10.1111/bju.12789. Epub 2014 Aug 11. BJU Int. 2015. PMID: 24784420 Free PMC article.

6

Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.

James H 3rd, Aleksic I, Bienz MN, Pieczonka C, Iannotta P, Albala D, Mariados N, Mouraviev V, Saad F. James H 3rd, et al. Urology. 2014 Jul;84(1):164-8. doi: 10.1016/j.urology.2013.12.071. Urology. 2014. PMID: 24976229

7

Testosterone therapy in prostate cancer: is it still a controversy?

Bart AS, Van Hoof A, Badre-Hume R, Selvarajah J, Robillard K, Albala DM. Bart AS, et al. Among authors: albala dm. Curr Opin Urol. 2022 Nov 1;32(6):598-606. doi: 10.1097/MOU.0000000000001039. Epub 2022 Sep 8. Curr Opin Urol. 2022. PMID: 36081393 Review.

8

Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.

Mouraviev V, Lee B, Patel V, Albala D, Johansen TE, Partin A, Ross A, Perera RJ. Mouraviev V, et al. Prostate Cancer Prostatic Dis. 2016 Mar;19(1):14-20. doi: 10.1038/pcan.2015.48. Epub 2015 Oct 27. Prostate Cancer Prostatic Dis. 2016. PMID: 26503110 Review.

9

Predicting non-organ-confined prostate cancer in men diagnosed after 2000.

Caire AA, Sun L, Lack BD, Lum K, Tang P, Stackhouse DA, Robertson CN, Mouraviev V, Polascik TJ, Albala DM, Moul JW. Caire AA, et al. Among authors: albala dm. Prostate Cancer Prostatic Dis. 2010 Sep;13(3):248-51. doi: 10.1038/pcan.2010.15. Epub 2010 Jun 1. Prostate Cancer Prostatic Dis. 2010. PMID: 20514082

10

A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.

Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, Droller MJ; PC B302/01 Study Group. Fradet Y, et al. J Urol. 2007 Jul;178(1):68-73; discussion 73. doi: 10.1016/j.juro.2007.03.028. Epub 2007 May 11. J Urol. 2007. PMID: 17499291 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

201 results

Search Page